journal article·2026-06Open access

A biomimetic nanoplatform enables shTHY1-mediated immunomodulation and cartilage remodeling for osteoarthritis therapy

Xinyue Hu, Zhuang Li, Xiaofei Li, Lingxiao Zhang, Yaqing Zhang

Abstract

Osteoarthritis (OA) is characterized by a chronic inflammatory microenvironment accompanied by elevated reactive oxygen species (ROS), synovial immune dysregulation, and progressive cartilage degeneration. While conventional pharmacological treatments often exhibit limited efficacy in halting disease advancement, we report a biomimetic, ROS-responsive nanoparticle (NPs) delivery system coated with macrophage membranes (MM-shTHY1-NPs) to achieve targeted therapy. The macrophage membrane (MM) coating not only improves retention and targeting toward inflamed synovial tissues, but also provides cytokine-scavenging capability that helps buffer the inflammatory microenvironment. Within the oxidative joint microenvironment, the ROS-responsive architecture of the NPs-facilitated by diselenide bonds-triggers the site-specific release of shTHY1 payloads. Importantly, we demonstrated the therapeutic relevance of THY1 silencing in OA microenvironment remodeling; both in vitro and in vivo experiments demonstrate that shTHY1 delivery effectively promotes macrophage repolarization from a pro-inflammatory M1 to an anti-inflammatory M2 phenotype. This phenotypic shift subsequently remodels the chondrocyte microenvironment, suppressing matrix metalloproteinase expression and attenuating cartilage degradation. The synergy between RNAi-mediated THY1 silencing and the cytokine-scavenging capability of the macrophage membrane coating resulted in enhanced therapeutic efficacy. Our findings suggest that this cell-membrane-coated nanoplatform provides a promising strategy for the treatment of inflammatory joint diseases, with potential advantages in biosafety, site-specific delivery, and translational feasibility.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Osteoarthritis Treatment and Mechanisms · Wound Healing and Treatments · Bone Tissue Engineering Materials

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (28)

Show source-provided references
1. Cartilage matrix-inspired biomimetic superlubricated nanospheres for treatment of osteoarthritis10.1016/j.biomaterials.2020.119931 ↗
2. Injectable natural polymer hydrogels for treatment of knee osteoarthritis10.1002/adhm.202101479 ↗
3. MRI-Visible mesoporous polydopamine nanoparticles with enhanced antioxidant capacity for osteoarthritis therapy10.1016/j.biomaterials.2023.122030 ↗
4. Reactive oxygen species-responsive and scavenging polyurethane nanoparticles for treatment of osteoarthritis in vivo10.1016/j.cej.2020.128147 ↗
5. A photothermal-triggered nitric oxide nanogenerator combined with siRNA for precise therapy of osteoarthritis by suppressing macrophage inflammation10.1039/C8NR10013F ↗
6. The ROS‐responsive scavenger with intrinsic antioxidant capability and enhanced immunomodulatory effects for cartilage protection and osteoarthritis remission
7. Biomimetic zwitterionic copolymerized chitosan as an articular lubricant10.1016/j.carbpol.2024.121821 ↗
8. A biomimetic lubricating nanosystem with responsive drug release for osteoarthritis synergistic therapy10.1002/adhm.202203245 ↗
9. Reactive oxygen species (ROS)-mediated M1 macrophage-dependent nanomedicine remodels inflammatory microenvironment for osteoarthritis recession
10. Opsonization inveigles macrophages engulfing carrier‐free Bilirubin/JPH203 nanoparticles to suppress inflammation for osteoarthritis therapy10.1002/advs.202400713 ↗
11. Polydopamine nanoparticles as dual-task platform for osteoarthritis therapy: a scavenger for reactive oxygen species and regulator for cellular powerhouses10.1016/j.cej.2021.129284 ↗
12. Cartilage repair in degenerative osteoarthritis mediated by squid type II collagen via immunomodulating activation of M2 macrophages, inhibiting apoptosis and hypertrophy of chondrocytes10.1016/j.biomaterials.2018.07.011 ↗
13. Glucosamine sulphate-loaded distearoyl phosphocholine liposomes for osteoarthritis treatment: combination of sustained drug release and improved lubrication10.1039/C9BM00201D ↗
14. Immunoregulation and anti-metalloproteinase bioactive injectable polysalicylate matrixgel for efficiently treating osteoarthritis
15. Artificial M2 macrophages for disease-modifying osteoarthritis therapeutics10.1016/j.biomaterials.2021.120865 ↗
16. Photothermal therapy of tuberculosis using targeting pre-activated macrophage membrane-coated nanoparticles10.1038/s41565-024-01618-0 ↗
17. Remodeling of the pro-inflammatory microenvironment in osteoarthritis via hydrogel-based photothermal therapy10.1007/s42114-024-00835-4 ↗
18. Oral mitochondrial transplantation using nanomotors to treat ischaemic heart disease10.1038/s41565-024-01681-7 ↗
19. Msx1(+) stem cells recruited by bioactive tissue engineering graft for bone regeneration10.1038/s41467-022-32868-y ↗
20. Notch signalling drives synovial fibroblast identity and arthritis pathology10.1038/s41586-020-2222-z ↗
21. Synovial inflammation in osteoarthritis progression10.1038/s41584-022-00749-9 ↗
22. Synovial macrophage and fibroblast heterogeneity in joint homeostasis and inflammation10.3389/fmed.2022.862161 ↗
23. Monocyte‐Derived macrophages‐synovial fibroblasts crosstalk unravels oncostatin signaling network as a driver of synovitis in osteoarthritis10.1002/art.43299 ↗
24. Biosilicification-mimicking chiral nanostructures for targeted treatment of inflammatory bowel disease10.1038/s41467-025-57890-8 ↗
25. Self-disassembling nanoparticles as oral nanotherapeutics targeting intestinal microenvironment10.1038/s41467-025-58513-y ↗
26. Defining inflammatory cell states in rheumatoid arthritis joint synovial tissues by integrating single-cell transcriptomics and mass cytometry10.1038/s41590-019-0378-1 ↗
27. Macrophage-membrane-coated nanoparticles for tumor-targeted chemotherapy10.1021/acs.nanolett.7b05263 ↗
28. Self‐Reinforced MOF‐Based nanogel alleviates osteoarthritis by long‐acting drug release10.1002/adma.202401094 ↗